One was the panel consisting of methylated BMP3/NDRG4/VIM/TFPI2/mutant KRAS, β-actin, and Hb-level (and later refined and commercialized as Cologuard®), which in stool detected CRC with 87% sensitivity, adenoma with 82% sensitivity, and demonstrated a specificity of 93% [46, 48, 66]. The gene discussed is KRAS; the disease is colorectal carcinoma.